Irbesartan Aurobindo (Irbesartan)

Irbesartan selectively blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. This results in vasodilation, reduced sodium and water retention, lower blood pressure, and decreased stress on the heart and kidneys.

The appropriate dose of Irbesartan is determined by the prescribing healthcare professional based on the patient’s condition, blood pressure response, renal function and other individual factors. Dosage adjustments are made according to clinical judgment.

Safety of Irbesartan during pregnancy has not been established, and it is generally avoided because of potential fetal risk. Limited data are available for breastfeeding; therefore, use is usually discouraged unless the benefit clearly outweighs the potential risk.

To place an order, submit an enquiry on the Irbesartan Aurobindo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with ACE inhibitors, Irbesartan offers a similar blood‑pressure‑lowering effect but with a lower incidence of cough. Unlike calcium‑channel blockers, it directly targets the renin‑angiotensin system, providing additional renal‑protective benefits, especially in patients with diabetic kidney disease.

Irbesartan tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Irbesartan is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the prescribing clinician’s instructions regarding timing and any required dose adjustments.

The most serious adverse reactions include angioedema (rapid swelling of the face, lips, tongue or throat), hyperkalemia (elevated blood potassium), and acute kidney injury. Patients should seek immediate medical attention if they experience swelling, severe dizziness, or sudden changes in kidney function.

Irbesartan should be avoided in individuals with known hypersensitivity to the drug, severe hepatic impairment, or in pregnant women unless the potential benefit justifies the risk. Patients with uncontrolled hyperkalemia or severe renal artery stenosis should also not use this medication.